
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2211767</article-id><article-id pub-id-type="publisher-id">20031690</article-id><article-id pub-id-type="doi">10.1084/jem.20031690</article-id><article-id pub-id-type="pmid">14734527</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Dual, HLA-B27 Subtype-dependent Conformation of a Self-peptide </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hülsmeyer</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fiorillo</surname><given-names>Maria Teresa</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bettosini</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sorrentino</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saenger</surname><given-names>Wolfram</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ziegler</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uchanska-Ziegler</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Institut für Kristallographie, Freie Universität Berlin,14195 Berlin, Germany</aff><aff id="aff2">
<label>2</label>Dipartimento di Biologia Cellulare e dello Sviluppo, Università ‘La Sapienza,’ 00185 Roma, Italy</aff><aff id="aff3">
<label>3</label>Institut für Immungenetik, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, 14050 Berlin, Germany</aff><author-notes><fn><p><text><SENT sid="1" pm="."><plain>Address correspondence to Wolfram Saenger, Institut für Kristallographie, Freie Universität Berlin, 14195 Berlin, Germany. </plain></SENT>
<SENT sid="2" pm="."><plain>Phone: 49-30-8385-3412; Fax: 49-30-8385-6702; email: saenger@chemie.fu-berlin.de; or to Andreas Ziegler, Institut für Immungenetik, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, 14050 Berlin, Germany. </plain></SENT>
<SENT sid="3" pm="."><plain>Phone: 49-30-4505-53501; Fax: 49-30-4505-53953; email: andreas.ziegler@charite.de </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><day>19</day><month>1</month><year>2004</year></pub-date><volume>199</volume><issue>2</issue><fpage>271</fpage><lpage>281</lpage><history><date date-type="received"><day>1</day><month>10</month><year>2003</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2003</year></date></history><permissions><copyright-statement>Copyright © 2004, The Rockefeller University Press</copyright-statement><license license-type="openaccess"><license-p>This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>The products of the human leukocyte antigen subtypes HLA-B*2705 and HLA-B*2709 differ only in residue 116 (Asp vs. His) within the peptide binding groove but are differentially associated with the autoimmune disease ankylosing spondylitis (AS); HLA-B*2705 occurs in AS-patients, whereas HLA-B*2709 does not. </plain></SENT>
<SENT sid="5" pm="."><plain>The subtypes also generate differential T cell repertoires as exemplified by distinct T cell responses against the self-peptide pVIPR (RRKWRRWHL). </plain></SENT>
<SENT sid="6" pm="."><plain>The crystal structures described here show that pVIPR binds in an unprecedented dual conformation only to HLA-B*2705 molecules. </plain></SENT>
<SENT sid="7" pm="."><plain>In one binding mode, peptide pArg5 forms a salt bridge to Asp116, connected with drastically different interactions between peptide and heavy chain, contrasting with the second, conventional conformation, which is exclusively found in the case of B*2709. </plain></SENT>
<SENT sid="8" pm="."><plain>These subtype-dependent differences in pVIPR binding link the emergence of dissimilar T cell repertoires in individuals with HLA-B*2705 or HLA-B*2709 to the buried Asp116/His116 polymorphism and provide novel insights into peptide presentation by major histocompatibility antigens. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>X-ray structure</kwd><kwd>major histocompatibility antigen</kwd><kwd>peptide binding modes</kwd><kwd>ankylosing spondylitis</kwd><kwd>residue 116</kwd></kwd-group></SecTag></article-meta><notes><fn-group><fn><p><text><SENT sid="9" pm="."><plain>Abbreviations used in this paper: AS, ankylosing spondylitis; β2m, β2-microglobulin; HC, heavy chain; rms, root mean square. </plain></SENT>
</text></p></fn></fn-group></notes></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="10" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>MHC class I antigens are cell surface glycoproteins consisting of a polymorphic transmembrane heavy chain (HC) noncovalently bound to β2-microglobulin (β2m; reference 1). </plain></SENT>
<SENT sid="12" pm="."><plain>The HC forms a groove with six pockets (A–F) for binding of proteolytic fragments derived from self- and nonself-proteins (2, 3). </plain></SENT>
<SENT sid="13" pm="."><plain>These peptides are presented to TCRs located on CTLs and initiate a cellular immune response leading to the destruction of the antigen-presenting cell if the peptide is derived from a nonself-protein. </plain></SENT>
<SENT sid="14" pm="."><plain>Several MHC class I alleles are associated with autoimmune diseases, and allele-specific binding of foreign or self-peptides by MHC class I molecules may be crucial to disease pathogenesis (4–8). </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>The association of the HLA class I allele HLA-B27 with ankylosing spondylitis (AS) and related spondyloarthropathies is among the strongest observed for any HLA gene (9, 10). </plain></SENT>
<SENT sid="16" pm="."><plain>Population analyses have shown that most of the common HLA-B27 subtypes, including the frequent B*2705 allele, are disease associated, whereas two subtypes, B*2706 and B*2709, are not (11). </plain></SENT>
<SENT sid="17" pm="."><plain>The B*2705 protein differs in only a single HC amino acid (Asp116) from B*2709 (His116) (12). </plain></SENT>
<SENT sid="18" pm="."><plain>This residue is located at the floor of the F pocket, which accommodates the COOH-terminal side chain of the bound peptide, and both subtypes can be distinguished by the peptides presented in vivo (13, 14). </plain></SENT>
<SENT sid="19" pm="."><plain>Despite some differences, in particular with regard to the COOH-terminal peptide residue, the majority of the peptides constituting the B*2705 repertoire were found to overlap with those from B*2709 and vice versa (14). </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>A self-peptide (pVIPR, previously termed VIP1R400–408, RRKWRRWHL) with potential arthritogenic properties (15) is derived from vasoactive intestinal peptide type 1 receptor and shows high sequence homology to a peptide from the latent membrane protein 2 (pLMP2, residues 236–244, RRRWRRLTV) of EBV (16). </plain></SENT>
<SENT sid="21" pm="."><plain>pVIPR can be presented by both subtypes, but the resulting T cell repertoires are distinct; B*2709 individuals very rarely possess pVIPR-specific T cells, whereas such T cells are more abundant in peripheral blood of healthy B*2705 persons and are very frequently present in patients suffering from AS (15). </plain></SENT>
<SENT sid="22" pm="."><plain>This indicates efficient thymic elimination of T cells specific for HLA-B27:pVIPR complexes in B*2709- but not in B*2705-positive individuals. </plain></SENT>
<SENT sid="23" pm="."><plain>Although these findings do not prove a causative role of pLMP2 and pVIPR in AS, they open the possibility to correlate structural properties of these subtypes with the retention (in B*2705) or elimination (in B*2709) of pVIPR-specific T cells. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>The two crystal structures described here show that B*2705 accommodates pVIPR in two different conformations, of which one is identical to that seen when complexed with B*2709, whereas the other diverges substantially. </plain></SENT>
<SENT sid="25" pm="."><plain>Combined with functional studies in which pVIPR-specific CTLs were used, these findings suggest a molecular explanation for inappropriate T cell selection by individuals with a disease-associated HLA-B27 subtype. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods"><title><text><SENT sid="26" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="27" pm="."><plain>HLA-B27–positive Donors. </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>Six patients with AS and one healthy donor were enrolled for this paper. HLA-B27 typing was performed using the HLA-B27 high resolution kit (Dynal). </plain></SENT>
<SENT sid="29" pm="."><plain>Five patients and the healthy donor were HLA-B*2705 positive, and one patient (LV) was HLA-B*2702 positive. </plain></SENT>
<SENT sid="30" pm="."><plain>Lymphoblastoid cell lines from these individuals were generated by in vitro transformation of B cells using the standard type 1 EBV isolate B95.8 (17). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="31" pm="."><plain>Generation of pVIPR-specific Cytotoxic T Lymphocyte Lines. </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>PBMCs were isolated on a gradient of lymphoprep and depleted of the CD4+ fraction by Dynabeads M-540 CD4 (Dynal). </plain></SENT>
<SENT sid="33" pm="."><plain>Cells were incubated at 2 × 104 cells/well in 96-well flat-bottom microplates, stimulated at an 0.5:1 stimulator/responder ratio with autologous EBV-transformed B cells prepulsed overnight with 8.5 μM pVIPR, and γ irradiated (200 Gy). </plain></SENT>
<SENT sid="34" pm="."><plain>They were grown in RPMI 1640 medium containing 10% heat-inactivated pooled human serum, 2 mM l-glutamine, 10 U/ml penicillin, and 100 μg/ml of streptomycin and in the presence of 20–100 U/ml of human rIL-2 (Boehringer). </plain></SENT>
<SENT sid="35" pm="."><plain>10 d later, cytotoxic T lymphocyte lines were restimulated as aforementioned. </plain></SENT>
<SENT sid="36" pm="."><plain>After 1 wk, they were tested for pVIPR specificity in a standard 51Cr-release assay using as targets T2 cells transfected with either B*2705 cDNA (T2-B*2705) or B*2709 cDNA (T2-B*2709), pulsed with 70 μM of the peptide, or used untreated. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="37" pm="."><plain>Expression, Purification, and Crystallization of the HLA-B27:pVIPR Complexes. </plain></SENT>
</text></title><p><text><SENT sid="38" pm="."><plain>HLA-B27:pVIPR protein complexes were produced as described previously (18, 19). </plain></SENT>
<SENT sid="39" pm="."><plain>The pVIPR peptide (RRKWRRWHL) was obtained by standard solid phase synthesis and purified by HPLC (Alta Bioscience). </plain></SENT>
<SENT sid="40" pm="."><plain>The purified protein complexes were used for crystallization at concentrations of 20 mg/ml (B*2705:pVIPR) and 16 mg/ml (B*2709: pVIPR), respectively, in TBS buffer (10 mM Tris HCl, pH 7.5, and 150 mM NaCl). </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>Using hanging drop vapor diffusion, crystals suitable for X-ray diffraction experiments were obtained from a PEG 8000 pH screen. </plain></SENT>
<SENT sid="42" pm="."><plain>As observed earlier for similar HLA-B27 complexes, streak seeding was indispensible to produce large single crystals. </plain></SENT>
<SENT sid="43" pm="."><plain>For B*2705:pVIPR, drops made from 1 μl of precipitant solution (0.1 M Tris HCl, pH 8.0, and 16% PEG 8000) and 1 μl of protein solution produced prismatic crystals with a maximum size of 400 × 250 × 250 μm. </plain></SENT>
<SENT sid="44" pm="."><plain>Using glycerol as cryoprotectant, the best dataset in terms of resolution (1.47 Å) was obtained at the BL2 beamline at BESSY-II, Berlin, Germany. </plain></SENT>
<SENT sid="45" pm="."><plain>In the case of B*2709:pVIPR, drops made of 1 μl of precipitant solution (0.1 M Tris HCl, pH 8.5, and 19% PEG 8000) and 1 μl of protein solution yielded platelike crystals with a maximum size of 300 × 200 × 100 μm. </plain></SENT>
<SENT sid="46" pm="."><plain>Cryo-cooled crystals of this complex (glycerol as cryoprotectant) allowed collection of a 2.2-Å resolution dataset at the X13 beamline at Deutsches Elektronen Synchrotron. </plain></SENT>
<SENT sid="47" pm="."><plain>Both datasets were collected at 100 K and processed with the HKL package (see Table I; reference 20). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48" pm="."><plain>Structure Determination. </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>The structure of HLA-B*2709:pVIPR was determined by molecular replacement using peptide-stripped B*2709:m9 (PDB code 1k5n) as a search model and program molrep (CCP4; reference 21). </plain></SENT>
<SENT sid="50" pm="."><plain>After rigid body refinement using refmac (22), the initial model was improved with ARP/wARP (23), and water molecules were included. </plain></SENT>
<SENT sid="51" pm="."><plain>Further improvement of the structure was achieved by iterative cycles of manual rebuilding using O (24) and restrained maximum-likelihood refinement with refmac comprising isotropic B factor adjustment. </plain></SENT>
<SENT sid="52" pm="."><plain>After translation, libration, and screw rotation refinement (25), the R value converged at 0.188 (Rfree, 0.244). </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>As the two HLA-B27:pVIPR complexes crystallized isomorphously, initial phases for B*2705:pVIPR were calculated from peptide-stripped B*2709:pVIPR with His116 replaced by alanine. </plain></SENT>
<SENT sid="54" pm="."><plain>This initial model was subjected to rigid body refinement followed by simulated annealing and energy minimization using CNS (26). </plain></SENT>
<SENT sid="55" pm="."><plain>ARP/wARP was used for improvement of the model and incorporation of water molecules and pVIPR in canonical conformation. </plain></SENT>
<SENT sid="56" pm="."><plain>After manual rebuilding, inclusion of alternate protein conformations, and atom positional refinement (refmac), there was still residual electron density in the peptide binding groove, to which an additional, noncanonical conformation of pVIPR could be fitted with an estimated occupancy of 0.5 for both peptide chains. </plain></SENT>
<SENT sid="57" pm="."><plain>Subsequent optimization of atomic displacement parameters decreased the R factor by 2.5% (Rfree, 2%) compared with isotropic refinement, justifying this procedure. </plain></SENT>
<SENT sid="58" pm="."><plain>Evaluation of anisotropy by parvati (27) showed the expected statistical distribution of 0.52 ± 0.14 for all atoms of the structure. </plain></SENT>
<SENT sid="59" pm="."><plain>The R value converged at 0.128 (Rfree 0.178). </plain></SENT>
<SENT sid="60" pm="."><plain>The equimolar distribution of the two pVIPR conformations in the B*2705 molecule was confirmed by an occupancy refinement performed with CNS. </plain></SENT>
<SENT sid="61" pm="."><plain>With the p6α conformation (see Results) omitted from the atomic coordinates, the occupancy of the central part of the peptide refined to occupancies ∼0.5, whereas that of p1, p2, p8, and p9 stayed with full occupancy. </plain></SENT>
<SENT sid="62" pm="."><plain>Similar results were obtained when only the p6α conformation was refined. </plain></SENT>
</text></p><p><text><SENT sid="63" pm="."><plain>In both structures, radiation-decarboxylated Asp and Glu that showed negative difference electron density were assigned occupancies &lt;1.0. </plain></SENT>
<SENT sid="64" pm="."><plain>The final models include all 276 residues of the HC, 100 residues of β2m (all 99 residues plus NH2-terminal Met), all nonhydrogen atoms of the pVIPR peptide, water, and glycerol (from the cryoprotectant). </plain></SENT>
<SENT sid="65" pm="."><plain>All ϕ/ψ angles lie in allowed regions of the Ramachandran plot (procheck; reference 28). </plain></SENT>
<SENT sid="66" pm="."><plain>Both structures were validated with whatcheck (29). </plain></SENT>
<SENT sid="67" pm="."><plain>Statistics are compiled in Table I. </plain></SENT>
<SENT sid="68" pm="."><plain>Superimpositions were performed using profit (30). </plain></SENT>
<SENT sid="69" pm="."><plain>Figures were generated using Grasp (31), povray (<ext-link ext-link-type="uri" xlink:href="http://www.povray.org">www.povray.org</ext-link>), molscript (32), povscript1 (33), and raster3D (34) together with a graphical interface (moldraw) developed by N. </plain></SENT>
<SENT sid="70" pm="."><plain>Sträter (Institut für Kristallographie, Freie Universität Berlin, Berlin, Germany; unpublished data). </plain></SENT>
<SENT sid="71" pm="."><plain>Molecular surfaces were calculated with MSMS (35). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl1" position="float"><label>Table I.</label><caption><p><text><SENT sid="72" pm="."><plain>Data Collection and Refinement Statistics </plain></SENT>
</text></p></caption><table-wrap-foot><fn id="tfn1"><label>a</label><p><text><SENT sid="73" pm="."><plain>Values in parentheses refer to the highest resolution shell. </plain></SENT>
</text></p></fn><fn id="tfn2"><label>b</label><p><text><SENT sid="74" pm="."><plain>Rsym = Σh Σi ∣ Ih,i − &lt;Ih&gt; ∣/ΣhΣiIh,i. </plain></SENT>
</text></p></fn><fn id="tfn3"><label>c</label><p><text><SENT sid="75" pm="."><plain>Rcryst = Σh ∣ Fo − Fc∣/Σ Fo Working set; no σ cut-off applied. </plain></SENT>
</text></p></fn><fn id="tfn4"><label>d</label><p><text><SENT sid="76" pm="."><plain>Rfree is the same as Rcryst, but calculated on 5% of the data excluded from refinement. </plain></SENT>
</text></p></fn><fn id="tfn5"><label>e</label><p><text><SENT sid="77" pm="."><plain>Estimated overall coordinate error based on Rfree as calculated by REFMAC 5.0. </plain></SENT>
</text></p></fn><fn id="tfn6"><label>f</label><p><text><SENT sid="78" pm="."><plain>Root mean squared deviation from target geometries. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="79" pm="."><plain>The atomic coordinates and structure amplitudes have been deposited in the Protein Data Bank (accession codes 1ogt [B*2705:pVIPR] and 1of 2 [B*2709:pVIPR]). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="80" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="81" pm="."><plain>General Features of the HLA-B27:pVIPR Structures. </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>HLA-B*2705:pVIPR and B*2709:pVIPR crystallized isomorphously (same space group and comparable unit cell constants), showing the typical MHC class I immunoglobulin-like folds (1) and refined to values of Rcryst = 12.8% and Rfree = 17.8% at 1.47 Å and Rcryst = 18.8% and Rfree = 24.4% at 2.20 Å resolution, respectively (Materials and Methods and Table I). </plain></SENT>
<SENT sid="83" pm="."><plain>In both structures, pVIPR is bound in the common canonical conformation (Fig. 1 A) found in other HLA-B27 molecules, exploiting all six pockets of the peptide binding groove for interaction with the HC (19, 36, 37). </plain></SENT>
<SENT sid="84" pm="."><plain>However, B*2705:pVIPR features an additional, grossly different noncanonical peptide conformation (Fig. 1 B). </plain></SENT>
<SENT sid="85" pm="."><plain>Both conformations found in B*2705 are present in a 1:1 ratio as shown by occupancy refinement. </plain></SENT>
<SENT sid="86" pm="."><plain>Despite this peculiarity in B*2705, the structures of HC and β2m of the two subtypes are practically indistinguishable (Cα root mean square [rms] deviation 0.2 Å), including almost all side chain atoms. </plain></SENT>
<SENT sid="87" pm="."><plain>The atoms contributing to the binding groove occupy the same positions in B*2705 as in B*2709, and extreme atomic displacement factors (thermal anisotropy), which could mask multiple conformations were also not detected for B*2705. </plain></SENT>
<SENT sid="88" pm="."><plain>It has to be emphasized that, due to the isomorphous crystal structures, the intermolecular crystal contacts in both B*2705:pVIPR conformations are comparable, demonstrating that the two different binding modes of pVIPR found only in B*2705 are an intrinsic feature due to the presence of Asp116 and not a crystallographic artifact. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><text><SENT sid="89" pm="."><plain>pVIPR conformations, atomic displacement ellipsoids, and B factors. </plain></SENT>
<SENT sid="90" pm="."><plain>(A) Superimposition of the canonical pVIPR conformations (p4α) found in B*2705 (blue) and B*2709 (gold). </plain></SENT>
<SENT sid="91" pm="."><plain>(B) The noncanonical pVIPR conformation (p6α, pink) observed only in B*2705. </plain></SENT>
<SENT sid="92" pm="."><plain>The peptides are viewed from the side of the α2 helix together with a molecular surface covering the floor and back of the binding groove. </plain></SENT>
<SENT sid="93" pm="."><plain>The subtype-specific residue 116 is indicated also (Asp116, yellow; His116, turquoise); the bidentate salt bridge to Asp116 is drawn with green dotted lines in B. </plain></SENT>
<SENT sid="94" pm="."><plain>The binding pockets A–F are shown in bold letters. </plain></SENT>
<SENT sid="95" pm="."><plain>Atomic displacement ellipsoids for pVIPR-p4α and -p6α in C and D are colored according to the equivalent isotropic temperature factors B (Å2) (see color bar). </plain></SENT>
<SENT sid="96" pm="."><plain>(E, left) Schematic description of side chain orientation when looking from the NH2 to the COOH terminus of pVIPR. </plain></SENT>
<SENT sid="97" pm="."><plain>Bottom of peptide binding groove indicated by “β-sheet” and side for T cell recognition by “TCR”. </plain></SENT>
<SENT sid="98" pm="."><plain>(E, right) The orientation of the peptide side chains in the p4α and p6α conformations as in E (left). </plain></SENT>
<SENT sid="99" pm="."><plain>The respective binding pockets (A–F) are indicated as well. </plain></SENT>
<SENT sid="100" pm="."><plain>It is clear from this representation and Fig. 1 (A and B) that the two pVIPR conformations show major differences only from pLys3 to pTrp7. </plain></SENT>
</text></p></caption><graphic xlink:href="20031690f1"/></fig></SecTag><p><text><SENT sid="101" pm="."><plain>In addition, there is a metal binding site with an octahedral coordination sphere formed by pHis8-Nɛ, His197-Nɛ (of a symmetry-related HC), and four water molecules. </plain></SENT>
<SENT sid="102" pm="."><plain>The cation is probably Mn2+ as inferred from coordination distances (38). </plain></SENT>
<SENT sid="103" pm="."><plain>The electron density and B factors of Mn2+ (19.7 Å2 in B*2705 and 42.3 Å2 in B*2709; the B values are different due to the different resolutions) (Fig. 2 , electron densities for Mn2+) suggest that the site is fully occupied. </plain></SENT>
<SENT sid="104" pm="."><plain>The presence of Mn2+ is a purification artifact that originates from a lysis buffer. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><text><SENT sid="105" pm="."><plain>Final electron density of pVIPR conformations in B*2705 and B*2709. </plain></SENT>
<SENT sid="106" pm="."><plain>Stereo images of the final 2Fo-Fc electron density contoured at 1 σ level, displayed in light green. </plain></SENT>
<SENT sid="107" pm="."><plain>The two B*2705:pVIPR conformations are shown in A, the respective B*2709 complex is shown in B. </plain></SENT>
<SENT sid="108" pm="."><plain>The peptides are color coded as in Fig. 1 (A and B): water molecules as red and Mn2+ as green spheres. </plain></SENT>
</text></p></caption><graphic xlink:href="20031690f2"/></fig></SecTag></sec><sec><title><text><SENT sid="109" pm="."><plain>HLA-B27 Subtype-dependent Peptide Conformations. </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>The different conformations of pVIPR in the binding groove of B*2705 are reflected in the backbone torsion angles of the peptide. </plain></SENT>
<SENT sid="111" pm="."><plain>In both structures, pVIPR is bound in the canonical conformation found regularly in crystal structures of MHC class I–nonapeptide complexes with main chain torsion angles (φ, ψ) of the extended β-strand type and only residue p4 (pTrp4) in right-handed α-helical conformation (Fig. 1 A, φ − 85.2° and ψ − 32.6°). </plain></SENT>
<SENT sid="112" pm="."><plain>The α-helical turn at position p4 results in a prominent kink directing the main chain “away” from the floor of the binding groove toward the solvent. </plain></SENT>
<SENT sid="113" pm="."><plain>Residues of pVIPR in this conformation (pVIPR-p4α) interact with all six pockets (Fig. 1 E, pockets A–F) provided by the binding groove, as found commonly for nonapeptides (1). </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>The additional peptide conformation found in B*2705 exhibits a pArg6 in α-form (Fig. 1 B, φ − 106.4° and ψ + 34.7° designated pVIPR-p6α) and both pVIPR-p4α and pVIPR-p6α are half occupied (Materials and Methods and Table I). </plain></SENT>
<SENT sid="115" pm="."><plain>pVIPR-p4α is virtually identical in both subtypes (Fig. 1 A, rms deviation 0.1 Å for nonhydrogen atoms). </plain></SENT>
<SENT sid="116" pm="."><plain>Between the p4α peptides in B*2705 and B*2709, there is only one minor difference in the orientation of the pArg6 guanidinium group as it is engaged in different hydrogen bonds. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="117" pm="."><plain>Conformation-dependent HLA-B27:pVIPR Interactions. </plain></SENT>
</text></title><p><text><SENT sid="118" pm="."><plain>At the peptide NH2- and COOH-termini, pArg1, pArg2, pHis8, and pLeu9 occupy identical positions in pVIPR-p4α and -p6α (Fig. 1, A, B, and E and Fig. 2 A). </plain></SENT>
<SENT sid="119" pm="."><plain>The interactions of pArg1 and pArg2 with A and B pocket residues correspond to those observed for the B*2709:s10R complex (PDB code 1JGD; reference 37); the side chain of pArg1 is sandwiched between the side chains of HC Arg62 (α1-helix) and Trp167 (α2-helix). </plain></SENT>
<SENT sid="120" pm="."><plain>In addition, the side chains of Arg62 and Glu163 (α2-helix) are linked by a water-mediated salt bridge (Fig. 3, A and B , bridge) that covers the deeply embedded pArg2. </plain></SENT>
<SENT sid="121" pm="."><plain>At the COOH terminus, pHis8 is solvent exposed as well (Figs. </plain></SENT>
<SENT sid="122" pm="."><plain>2 and 3), and pLeu9 is accommodated in the F pocket. </plain></SENT>
<SENT sid="123" pm="."><plain>The carboxy group of pLeu9 forms the common polar interactions with Tyr84-Oη, Thr143-Oγ, and Lys146-Nζ (1), and the aliphatic pLeu9 side chain forms hydrophobic interactions with the side chains of Leu81, Leu95, Tyr123, and Trp147 (19). </plain></SENT>
<SENT sid="124" pm="."><plain>Because the side chain of pLeu9 is too short to engage in any direct contacts with Asp116 (B*2705) or His116 (B*2709), there are no significant differences in the F pockets between both subtypes. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><text><SENT sid="125" pm="."><plain>Molecular surfaces and contacts of pVIPR in the p4α and p6α conformations. </plain></SENT>
<SENT sid="126" pm="."><plain>(A and B) Molecular surfaces show the central part of the B*2705 peptide binding groove in gray and the pVIPR peptide in the p4α and p6α conformations (color coded as in Fig. 1 [A and B]). </plain></SENT>
<SENT sid="127" pm="."><plain>The binding groove has been rendered semi-transparent, allowing also the inspection of buried side chains exhibiting conformational differences. </plain></SENT>
<SENT sid="128" pm="."><plain>In A, the view is TCR-like, straight onto the peptide, whereas in B (rotated by 90° about a horizontal axis), the view is through the α2 helix. </plain></SENT>
<SENT sid="129" pm="."><plain>The center section of the peptide shows clear shape differences between the p4α and p6α conformations. </plain></SENT>
<SENT sid="130" pm="."><plain>(C) pVIPR hydrogen bonding in p4α and p6α, color coded as in Fig 1 (A and B). </plain></SENT>
<SENT sid="131" pm="."><plain>Only side chains with different binding modes (residues p3–p7) are shown. </plain></SENT>
<SENT sid="132" pm="."><plain>The binding groove's secondary structure is represented as gray spirals (α helices) and arrows (β strands) together with selected interacting residues (carbon atoms, gray; oxygens, red; and nitrogens, blue). </plain></SENT>
<SENT sid="133" pm="."><plain>Hydrogen bonds are depicted as black broken lines, the pArg5–Asp116 bidentate salt bridge is depicted as green dotted lines, and water molecules are depicted as dark blue spheres. </plain></SENT>
<SENT sid="134" pm="."><plain>(D) Electrostatic surfaces of both pVIPR conformations. </plain></SENT>
<SENT sid="135" pm="."><plain>Red indicates negative, blue indicates positive surface charge, and gray areas are uncharged. </plain></SENT>
<SENT sid="136" pm="."><plain>The view is looking straight onto the binding groove as in A. </plain></SENT>
<SENT sid="137" pm="."><plain>The border of the peptides is highlighted in white. </plain></SENT>
</text></p></caption><graphic xlink:href="20031690f3"/></fig></SecTag><p><text><SENT sid="138" pm="."><plain>In contrast to the NH2- and COOH-terminal residues, the central sections of pVIPR-p4α and -p6α, pLys3 to pTrp7, which are principally accessible for recognition by a TCR, differ drastically with maximal disparity at pArg5, 3.7 Å for Cα, and 16.5 Å for Nη2 (Table II and Figs. </plain></SENT>
<SENT sid="139" pm="."><plain>1, A, B, and E and Fig. 2 A and Figs. </plain></SENT>
<SENT sid="140" pm="."><plain>3 and 4) . </plain></SENT>
<SENT sid="141" pm="."><plain>In pVIPR-p4α, side chains of pTrp4 and pArg5 are exposed to solvent, but in pVIPR-p6α, pArg5 is locked within the binding groove, its guanidinium group forming a bidentate salt bridge with the B*2705 subtype-specific Asp116 at the interface of the C, E, and F pockets (Figs. </plain></SENT>
<SENT sid="142" pm="."><plain>1 B and 2 C and Figs. </plain></SENT>
<SENT sid="143" pm="."><plain>3 and 4). </plain></SENT>
<SENT sid="144" pm="."><plain>In pVIPR-p6α, residues pTrp4 and pArg6 flanking pArg5 are maximally exposed to solvent and stacked (Fig. 1 B and Fig. 2). </plain></SENT>
<SENT sid="145" pm="."><plain>As a consequence of the structural differences around pArg5, the solvent-accessible surface areas of pVIPR-p4α and pVIPR-p6α have different size (160 Å2 for pVIPR-p4α and 124 Å2 for pVIPR-p6α), shape (Fig. 3, A and B), and charge distribution (Fig. 3 D) so that several prerequisites for differential recognition by a TCR are provided. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl2" position="float"><label>Table II.</label><caption><p><text><SENT sid="146" pm="."><plain>Comparison of Peptide Coordination in the p4α and p6α Binding Modes of B*2705:pVIPR </plain></SENT>
</text></p></caption><table-wrap-foot><fn><p><text><SENT sid="147" pm="."><plain>Only direct contacts are included, and water-mediated interactions are omitted. </plain></SENT>
<SENT sid="148" pm="."><plain>Interacting atoms are specified for polar interactions only because v.d. </plain></SENT>
<SENT sid="149" pm="."><plain>Waals contacts are too numerous and less specific. </plain></SENT>
</text></p></fn><fn id="tfn7"><label>*</label><p><text><SENT sid="150" pm="."><plain>β-sheet floor. </plain></SENT>
</text></p></fn><fn id="tfn8"><label>‡</label><p><text><SENT sid="151" pm="."><plain>Intrapeptide contacts. </plain></SENT>
</text></p></fn><fn id="tfn9"><label>§</label><p><text><SENT sid="152" pm="."><plain>Helix α2. </plain></SENT>
</text></p></fn><fn id="tfn10"><label>¶</label><p><text><SENT sid="153" pm="."><plain>Helix α1. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="fig4" position="float"><label>Figure 4.</label><caption><p><text><SENT sid="154" pm="."><plain>Conformation-dependent peptide contacts with F-pocket residues. </plain></SENT>
<SENT sid="155" pm="."><plain>The F-pocket architecture and intermolecular interactions in B*2705:pVIPR-p4α (left) and -p6α (right), with relevant part of the peptide shown (same color code as in Fig. 1 [A and B]). </plain></SENT>
<SENT sid="156" pm="."><plain>Fully occupied water molecules are shown in dark blue and partially occupied ones (related to a specific peptide conformation) are in turquoise. </plain></SENT>
<SENT sid="157" pm="."><plain>The space occupied by pArg5-p6α is filled by water molecules in the p4α binding mode. </plain></SENT>
<SENT sid="158" pm="."><plain>The view is looking along the binding groove with the peptide COOH terminus in front. </plain></SENT>
</text></p></caption><graphic xlink:href="20031690f4"/></fig></SecTag><p><text><SENT sid="159" pm="."><plain>As both p4α and p6α are roughly half occupied in the B*2705 structure (Materials and Methods), approximate energetic equivalence of the two conformations seems likely. </plain></SENT>
<SENT sid="160" pm="."><plain>This is suggested by the temperature factors for the peptide in the two conformations (Fig. 1, C and D) that are very similar: in B*2705, the average (isotropic) B factor for all peptide atoms is 14.8 Å2 (range 10.0–25.9 Å2) for p4α and 17.4 Å2 (range 10.8–31.9 Å2) for p6α. </plain></SENT>
<SENT sid="161" pm="."><plain>The highest flexibility found for pTrp4-p6α (∼30 Å2) is still relatively low on an absolute scale, and marked atomic displacement as indicated by large B factors is only found in the side chains of pTrp4, pArg6, and pTrp7 for both p4α and p6α (Fig. 1, C and D). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="162" pm="."><plain>Peptide Conformation-dependent Recognition of HLA-B27 Subtypes by T Cells. </plain></SENT>
</text></title><p><text><SENT sid="163" pm="."><plain>Previous analyses of autoreactive CTL lines from individuals typing as B*2705 or B*2709 have indicated that pVIPR-specific CTLs are frequently observed in patients with AS, although they occur also in healthy B*2705 individuals. </plain></SENT>
<SENT sid="164" pm="."><plain>In contrast, such CTLs are only rarely found in B*2709 individuals (15). </plain></SENT>
<SENT sid="165" pm="."><plain>We extended these studies, in particular in an attempt to identify CTLs exclusively reactive against B*2705 that might indicate immunogenicity also of B*2705-p6α. </plain></SENT>
<SENT sid="166" pm="."><plain>The results shown in Table III are based on 39 CTL lines, 17 of which are already published (15) and 22 were newly obtained from six AS patients (five B*2705 and one B*2702) and one B*2705 healthy control. </plain></SENT>
<SENT sid="167" pm="."><plain>The CTLs are grouped as preferentially recognizing peptide-transporter–deficient T2-B*2705 or T2-B*2709 cells, both subtypes with approximately equal efficiency, or exclusively T2-B*2705. </plain></SENT>
<SENT sid="168" pm="."><plain>No CTL recognizing only T2-B*2709 was observed, although pVIPR was used at a high concentration (70 μM). </plain></SENT>
<SENT sid="169" pm="."><plain>This experimental setup was chosen to maximize the chances to detect reactivity genuinely specific for B*2705:pVIPR complexes. </plain></SENT>
<SENT sid="170" pm="."><plain>Dose–response curves for the reactivity of pVIPR-specific CTLs have already been determined (15); at lower peptide concentrations, T2-B*2709 target cells tended to be lysed at higher efficiency than T2-B*2705 cells. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl3" position="float"><label>Table III.</label><caption><p><text><SENT sid="171" pm="."><plain>Reactivity of CTLs from HLA-B27–positive Subjects towards the pVIPR Peptide in the Context of Either B*2705 or B*2709 Molecules </plain></SENT>
</text></p></caption><table-wrap-foot><fn id="tfn11"><label>a</label><p><text><SENT sid="172" pm="."><plain>Five donors (MP, EP, AS, AB, and MD) are HLA-B*2705–positive patients with AS. </plain></SENT>
<SENT sid="173" pm="."><plain>LV is an HLA-B*2702–positive patient with AS, and CV is a healthy HLA-B*2705–positive individual. </plain></SENT>
<SENT sid="174" pm="."><plain>The results summarize the data obtained in two cytotoxicity experiments. </plain></SENT>
<SENT sid="175" pm="."><plain>Background (specific lysis of unpulsed T2-B*2705 and T2-B*2709) was &lt;12%. </plain></SENT>
</text></p></fn><fn id="tfn12"><label>b</label><p><text><SENT sid="176" pm="."><plain>The difference in the percentage of specific lysis between T2-B*2705 and T2-B*2709 cells after background subtraction was &gt;20%. </plain></SENT>
</text></p></fn><fn id="tfn13"><label>c</label><p><text><SENT sid="177" pm="."><plain>The difference in the percentage of specific lysis between T2-B*2705 and T2-B*2709 cells after background subtraction was &lt;20%. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="178" pm="."><plain>The majority of the CTLs lysed both T2-B*2705 and T2-B*2709 equally well (Table III). </plain></SENT>
<SENT sid="179" pm="."><plain>However, there were exceptions showing a clear preference for T2-B*2709 cells. </plain></SENT>
<SENT sid="180" pm="."><plain>This was not unexpected because it has previously been found that B*2709 antigens present pVIPR more efficiently than B*2705 (15). </plain></SENT>
<SENT sid="181" pm="."><plain>Only one CTL line was found (EP76) that selectively reacted with pVIPR presented by T2-B*2705 cells. </plain></SENT>
<SENT sid="182" pm="."><plain>The complete lack of reactivity against the B*2709:pVIPR complex, even at the high peptide concentration used, indicates that EP76 is directed against a structure different from B*2705:pVIPR-p4α because of the extreme structural similarity of B*2709:pVIPR and the p4α binding mode in B*2705 (Fig. 1 A). </plain></SENT>
<SENT sid="183" pm="."><plain>In contrast, five further CTLs from the AS-patient EP reacted with both T2-B*2705 and T2-B*2709 cells. </plain></SENT>
</text></p><p><text><SENT sid="184" pm="."><plain>However, it must be pointed out that oligoclonal CTL lines were used in these studies. </plain></SENT>
<SENT sid="185" pm="."><plain>Therefore, it appears possible that noncross-reactive CTL clones may be concealed in the population of cells exhibiting cross-reactivity, resulting in a lower degree of lysis of B*2709 target cells, and leading to an underestimation of the immunogenicity of the p6α conformation in B*2705. </plain></SENT>
<SENT sid="186" pm="."><plain>15.4% of the CTL lines lysed B*2705:pVIPR targets more efficiently than T2-B*2709:pVIPR cells (Table III). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="187" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="188" pm="."><plain>A fundamental deviation from the single binding mode found in all previously determined MHC class I:peptide complexes is the dual conformation of pVIPR in B*2705. </plain></SENT>
<SENT sid="189" pm="."><plain>This feature is of considerable interest both from structural and immunological points of view. </plain></SENT>
<SENT sid="190" pm="."><plain>Only one exception to the single binding mode of peptides has been described so far in the crystal structure of the rat RT1-Aa antigen in complex with the exceptionally long 13-mer peptide MTF-E. </plain></SENT>
<SENT sid="191" pm="."><plain>Two entirely different MTF-E conformations were found that are possibly associated with crystal packing effects (39). </plain></SENT>
<SENT sid="192" pm="."><plain>Because they could consequently represent nonphysiological artifacts, the two conformations and the reasons why MTF-E does not adopt a single binding mode are different from those reported here. </plain></SENT>
</text></p><p><text><SENT sid="193" pm="."><plain>The simultaneous occurrence of pVIPR-p4α and pVIPR-p6α in B*2705 may be static or dynamic. </plain></SENT>
<SENT sid="194" pm="."><plain>If static, the analyzed crystals would be composed of approximately equal amounts of two cocrystallizing asymmetric units: one containing pVIPR-p4α and the other pVIPR-p6α. </plain></SENT>
<SENT sid="195" pm="."><plain>If dynamic, the peptide would change continually from one conformation to the other within the binding groove, using fixed NH2- and COOH-terminal amino acids with pivot points located at or close to the main chain connections of p2-p3 and p7-p8, respectively (Figs. </plain></SENT>
<SENT sid="196" pm="."><plain>2 A and 3 C). </plain></SENT>
<SENT sid="197" pm="."><plain>Currently, we cannot distinguish between static and dynamic modes of peptide binding, but spectroscopic methods (40) or X-ray analyses of crystals produced at different temperatures may eventually provide an answer. </plain></SENT>
</text></p><p><text><SENT sid="198" pm="."><plain>Thus far, the presentation of a peptide by an MHC molecule in a single, defined conformation has been considered a prerequisite for positive and negative selection of T cells within the thymus (41). </plain></SENT>
<SENT sid="199" pm="."><plain>The two drastically different binding modes of pVIPR to B*2705 show that this assumption might be an oversimplification. </plain></SENT>
<SENT sid="200" pm="."><plain>A peptide changing its conformation dynamically within the groove could possibly preclude high-affinity interaction with the two CDR3 regions of a TCR (42, 43), whereas a static conformation might allow a more efficient recognition. </plain></SENT>
<SENT sid="201" pm="."><plain>The rare occurrence of pVIPR-specific CTL in B*2709 individuals suggests that the B*2709:pVIPR complex can indeed serve in establishing tolerance (15). </plain></SENT>
<SENT sid="202" pm="."><plain>Conversely, the number of B*2705:pVIPR-p4α and -p6α complexes might fall below the epitope density threshold required for negative selection (44, 45), leading to the frequent presence of autoreactive, pVIPR-specific CTL (15). </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>The CTL lines analyzed here seem to possess relatively low affinity (15), questioning the presentation of the VIPR-derived peptide under physiological conditions, and suggesting the use of VIPR transfectants in cytotoxicity studies. </plain></SENT>
<SENT sid="204" pm="."><plain>However, even when testing the reactivity of CTLs against EBV-derived peptides, lysis of target cells is rarely observed (15, 46). </plain></SENT>
<SENT sid="205" pm="."><plain>At least the viral peptides are surely processed and presented; comparative studies with transfectants are usually unsuccessful. </plain></SENT>
<SENT sid="206" pm="."><plain>In addition, a COOH-terminal pLeu9 as seen in pVIPR does not present an obstacle for efficient proteasomal processing (47) and transport to the endoplasmic reticulum, as shown by peptide elution studies from B*2705 and B*2709 molecules (14). </plain></SENT>
<SENT sid="207" pm="."><plain>The high number of pVIPR-specific CTLs in some B*2705 individuals (15) might be explained by selective increase (clonal expansion) due to cross-reaction. </plain></SENT>
<SENT sid="208" pm="."><plain>This is not unlikely because TCR cross-reactivity is mandatory for the control of infections (48–52). </plain></SENT>
<SENT sid="209" pm="."><plain>In the case discussed here, the pVIPR cross-reactive nonself antigen could be the EBV-derived pLMP2 (15, 16, 53). </plain></SENT>
<SENT sid="210" pm="."><plain>Convincing examples of molecular mimicry between viral and self-proteins have already been identified (51, 52). </plain></SENT>
</text></p><p><text><SENT sid="211" pm="."><plain>Unconventional peptide binding modes distantly resembling that observed for the p6α conformation in B*2705:pVIPR have occasionally been found in other MHC:peptide complexes as well (18, 54, 55), but the involvement of a strategic subtype-specific residue at the floor of the binding groove is unprecedented. </plain></SENT>
<SENT sid="212" pm="."><plain>The detection of p6α in B*2705:pVIPR but not in the closely related B*2709:pVIPR complex is obviously a consequence of the combined presence of the allele-specific residue Asp116 (B*2705) and a specific peptide sequence with Arg at position 5. </plain></SENT>
<SENT sid="213" pm="."><plain>The larger size and neutral or positive charge of His116 compared with Asp116 would interfere sterically and electrostatically if the pArg5 side chain were bound to the F pocket (Fig. 1 A). </plain></SENT>
<SENT sid="214" pm="."><plain>The binding of the peptide COOH-terminal pLeu9 to the F pocket brings a further constraint into play: to avoid clashes, it is likely that the side chain of this residue has to be small and hydrophobic, but not positively charged to prevent competition with another basic amino acid (in this instance, pArg5) that contacts Asp116. </plain></SENT>
</text></p><p><text><SENT sid="215" pm="."><plain>The paucity of peptides with pArg5, such as pLMP2, which have been found to be presented by HLA-B27 molecules under natural conditions (14, 16), makes it difficult to provide an estimate of the generality of the p6α conformation, let alone a dual peptide binding mode, in HLA-B27 molecules. </plain></SENT>
<SENT sid="216" pm="."><plain>We have found a few further peptides derived from self- as well as microbial proteins that have in common not only an Arg residue but even the WRR motif (unpublished data). </plain></SENT>
<SENT sid="217" pm="."><plain>As it seems conceivable that some of these peptides share the unorthodox structural features of pVIPR when complexed with the B*2705 subtype, analyses with these novel peptides are underway to examine the possibility that the WRR motif represents a sequence with direct involvement in AS pathogenesis. </plain></SENT>
<SENT sid="218" pm="."><plain>With only very few structures of HLA-B27:peptide complexes solved to date (Results; references 19, 36, 37), it seems premature to engage in a speculation on the prerequisites for a dual peptide conformation. </plain></SENT>
</text></p><p><text><SENT sid="219" pm="."><plain>However, the pVIPR-p6α peptide binding mode and its subtype dependency is not a unique, serendipitous finding. </plain></SENT>
<SENT sid="220" pm="."><plain>We have observed recently that the sequence-related pLMP2 peptide (16) binds in p4α-like form to B*2709 but in p6α-like conformation to B*2705, with pArg5 again forming a bidentate salt bridge with Asp116 (unpublished data). </plain></SENT>
<SENT sid="221" pm="."><plain>Therefore, the noncanonical binding mode involving residue 116 as observed for one of the conformations in B*2705:pVIPR and even its subtype dependency can be found in other HLA-B27:peptide complexes as well. </plain></SENT>
<SENT sid="222" pm="."><plain>Most AS-associated HLA-B27 alleles encode Asp116, whereas this residue is Tyr (B*2706) or His (B*2709) in the two subtypes not associated with AS (7). </plain></SENT>
</text></p><p><text><SENT sid="223" pm="."><plain>A constellation similar to that of the B*2705/B*2709 pair is found in A*68012 (Asp116) and A*6807 (His116; reference 56), or in B*3501 (Ser116) and B*3503 (Phe116; reference 57), but comparative structural studies have not been performed for these proteins. </plain></SENT>
<SENT sid="224" pm="."><plain>Among further HLA class I genes, approximately half of the HLA-A alleles encode Asp116, and nearly all others encode Tyr116 that occurs also in a smaller number of HLA-B and HLA-C antigens, in which Asp116 is rarely represented (58). </plain></SENT>
<SENT sid="225" pm="."><plain>However, the mere availability of Asp116 is not sufficient for a basic residue in the middle of a peptide to engage in a p6α-like binding mode. </plain></SENT>
<SENT sid="226" pm="."><plain>This is exemplified by the HLA-A*0201:MAGE-A4 complex (59) or HLA-B*4402 and B*4403 complexed with an HLA-DP–derived peptide (60): these peptides exhibit Arg either at position 5 or 6 that are solvent exposed and not buried. </plain></SENT>
<SENT sid="227" pm="."><plain>Other residues on the floor of the binding groove could principally also be involved in noncanonical anchoring modes such as the HC residues 97, 99, and 114, which are, like residue 116, highly polymorphic in HLA class I molecules (61). </plain></SENT>
<SENT sid="228" pm="."><plain>For example, HLA-B*3501 presents an EBV-derived nonapeptide with pAsp5 contacting Arg97 and Tyr99 (18). </plain></SENT>
<SENT sid="229" pm="."><plain>Clearly, a nonconventional peptide anchoring could be more frequent than currently envisaged. </plain></SENT>
</text></p><p><text><SENT sid="230" pm="."><plain>Polymorphisms within the MHC class I peptide binding groove as shown here may influence peptide presentation and T cell repertoire selection (1, 4, 7, 15, 62–64), but a dual peptide presentation mode as found in B*2705 that depends on the HLA-B27 subtype-specific amino acid exchange is novel. </plain></SENT>
<SENT sid="231" pm="."><plain>Distinct pVIPR presentation modes and differential AS-association of B*2705 and B*2709 may be linked in the course of the development of AS (15), although other factors influencing AS initiation and progression have to be taken into consideration, among them possible polymorphisms of HLA-B–linked genes (65–67). </plain></SENT>
<SENT sid="232" pm="."><plain>Our results support certain models of AS–pathogenesis that can incorporate differential peptide display by HLA-B27 subtypes, such as the arthritogenic peptide theory (4, 7), in particular in the modified form proposed by us (15), or the β2m-deposition hypothesis (68). </plain></SENT>
</text></p><p><text><SENT sid="233" pm="."><plain>HLA subtype-dependent differential presentation of peptides in noncanonical conformations due to HLA class I HC polymorphisms at residue 116 might also be connected to the pathogenesis of other disease states, such as the rate of the progression to AIDS in HIV-positive patients (57) or the outcome of bone marrow transplants between unrelated individuals (69). </plain></SENT>
<SENT sid="234" pm="."><plain>In conclusion, our results provide an unexpected twist regarding the mode of peptide display as a single, structurally unaltered MHC molecule can present a given peptide in two entirely different binding modes, depending only on a buried HC amino acid polymorphism. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="235" pm="."><plain>The authors thank all patients and the healthy proband for their participation in this paper. </plain></SENT>
<SENT sid="236" pm="."><plain>We are grateful to P.G. </plain></SENT>
<SENT sid="237" pm="."><plain>Coulie, J.A. </plain></SENT>
<SENT sid="238" pm="."><plain>López de Castro, and D.J. </plain></SENT>
<SENT sid="239" pm="."><plain>Schendel for discussions and comments on the manuscript; to M. </plain></SENT>
<SENT sid="240" pm="."><plain>Rühl for excellent technical assistance; and to U. </plain></SENT>
<SENT sid="241" pm="."><plain>Müller, S. </plain></SENT>
<SENT sid="242" pm="."><plain>Popov, and R. </plain></SENT>
<SENT sid="243" pm="."><plain>Hillig for help at the synchrotron facilities. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="244" pm="."><plain>This work was financially supported by the Deutsche Forschungsgemeinschaft (SFB 449), Berliner Krebsgesellschaft, Monika Kutzner-Stiftung, Berlin, Sonnenfeld-Stiftung, Berlin, Fonds der Chemischen Industrie, COFIN 2001, and Istituto Pasteur Fondazione Cenci-Bolognetti. </plain></SENT>
<SENT sid="245" pm="."><plain>Data collection at Deutsches Elektronen Synchrotron was supported by a European Community grant to the European Molecular Biology Laboratory Outstation in Hamburg. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><ref id="bib1"><text><SENT sid="246" pm="."><plain>1Madden, D.R. 1995. </plain></SENT>
<SENT sid="247" pm="."><plain>The three-dimensional structure of peptide-MHC complexes. Annu. </plain></SENT>
<SENT sid="248" pm="."><plain>Rev. </plain></SENT>
<SENT sid="249" pm="."><plain>Immunol. 13:587–622. <?supplied-pmid 7612235?>7612235 </plain></SENT>
</text></ref><ref id="bib2"><text><SENT sid="250" pm="."><plain>2Saper, M.A., P.J. </plain></SENT>
<SENT sid="251" pm="."><plain>Bjorkman, and D.C. </plain></SENT>
<SENT sid="252" pm="."><plain>Wiley. 1991. </plain></SENT>
<SENT sid="253" pm="."><plain>Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J. </plain></SENT>
<SENT sid="254" pm="."><plain>Mol. </plain></SENT>
<SENT sid="255" pm="."><plain>Biol. 219:277–319. <?supplied-pmid 2038058?>2038058 </plain></SENT>
</text></ref><ref id="bib3"><text><SENT sid="256" pm="."><plain>3Matsumura, M., D.H. </plain></SENT>
<SENT sid="257" pm="."><plain>Fremont, P.A. </plain></SENT>
<SENT sid="258" pm="."><plain>Peterson, and I.A. </plain></SENT>
<SENT sid="259" pm="."><plain>Wilson. 1992. </plain></SENT>
<SENT sid="260" pm="."><plain>Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science. 257:927–934. <?supplied-pmid 1323878?>1323878 </plain></SENT>
</text></ref><ref id="bib4"><text><SENT sid="261" pm="."><plain>4Benjamin, R., and P. </plain></SENT>
<SENT sid="262" pm="."><plain>Parham. 1990. </plain></SENT>
<SENT sid="263" pm="."><plain>Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol. </plain></SENT>
<SENT sid="264" pm="."><plain>Today. 11:137–142. <?supplied-pmid 2187471?>2187471 </plain></SENT>
</text></ref><ref id="bib5"><text><SENT sid="265" pm="."><plain>5Szpak, Y., J.C. </plain></SENT>
<SENT sid="266" pm="."><plain>Vieville, T. </plain></SENT>
<SENT sid="267" pm="."><plain>Tabary, M.C. </plain></SENT>
<SENT sid="268" pm="."><plain>Naud, M. </plain></SENT>
<SENT sid="269" pm="."><plain>Chopin, C. </plain></SENT>
<SENT sid="270" pm="."><plain>Edelson, J.H. </plain></SENT>
<SENT sid="271" pm="."><plain>Cohen, J. </plain></SENT>
<SENT sid="272" pm="."><plain>Dausset, Y. de Kozak, and M. </plain></SENT>
<SENT sid="273" pm="."><plain>Pla. 2001. </plain></SENT>
<SENT sid="274" pm="."><plain>Spontaneous retinopathy in HLA-A29 transgenic mice. Proc. </plain></SENT>
<SENT sid="275" pm="."><plain>Natl. </plain></SENT>
<SENT sid="276" pm="."><plain>Acad. </plain></SENT>
<SENT sid="277" pm="."><plain>Sci. </plain></SENT>
<SENT sid="278" pm="."><plain>USA. 98:2572–2576. <?supplied-pmid 11226280?>11226280 </plain></SENT>
</text></ref><ref id="bib6"><text><SENT sid="279" pm="."><plain>6Liblau, R.S., F.S. </plain></SENT>
<SENT sid="280" pm="."><plain>Wong, L.T. </plain></SENT>
<SENT sid="281" pm="."><plain>Mars, and P. </plain></SENT>
<SENT sid="282" pm="."><plain>Santamaria. 2002. </plain></SENT>
<SENT sid="283" pm="."><plain>Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity. 17:1–6. <?supplied-pmid 12150886?>12150886 </plain></SENT>
</text></ref><ref id="bib7"><text><SENT sid="284" pm="."><plain>7Ramos, M., and J.A. </plain></SENT>
<SENT sid="285" pm="."><plain>Lopez de Castro. 2002. </plain></SENT>
<SENT sid="286" pm="."><plain>HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens. 60:191–205. <?supplied-pmid 12445302?>12445302 </plain></SENT>
</text></ref><ref id="bib8"><text><SENT sid="287" pm="."><plain>8Trudeau, J.D., C. </plain></SENT>
<SENT sid="288" pm="."><plain>Kelly-Smith, C.B. </plain></SENT>
<SENT sid="289" pm="."><plain>Verchere, J.F. </plain></SENT>
<SENT sid="290" pm="."><plain>Elliott, J.P. </plain></SENT>
<SENT sid="291" pm="."><plain>Dutz, D.T. </plain></SENT>
<SENT sid="292" pm="."><plain>Finegood, P. </plain></SENT>
<SENT sid="293" pm="."><plain>Santamaria, and R. </plain></SENT>
<SENT sid="294" pm="."><plain>Tan. 2003. </plain></SENT>
<SENT sid="295" pm="."><plain>Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J. </plain></SENT>
<SENT sid="296" pm="."><plain>Clin. </plain></SENT>
<SENT sid="297" pm="."><plain>Invest. 111:217–223. <?supplied-pmid 12531877?>12531877 </plain></SENT>
</text></ref><ref id="bib9"><text><SENT sid="298" pm="."><plain>9Brewerton, D.A., F.D. </plain></SENT>
<SENT sid="299" pm="."><plain>Hart, A. </plain></SENT>
<SENT sid="300" pm="."><plain>Nicholls, M. </plain></SENT>
<SENT sid="301" pm="."><plain>Caffrey, D.C. </plain></SENT>
<SENT sid="302" pm="."><plain>James, and R.D. </plain></SENT>
<SENT sid="303" pm="."><plain>Sturrock. 1973. </plain></SENT>
<SENT sid="304" pm="."><plain>Ankylosing spondylitis and HLA-B27. Lancet. 1:904–907. <?supplied-pmid 4123836?>4123836 </plain></SENT>
</text></ref><ref id="bib10"><text><SENT sid="305" pm="."><plain>10Schlosstein, L., P.I. </plain></SENT>
<SENT sid="306" pm="."><plain>Terasaki, R. </plain></SENT>
<SENT sid="307" pm="."><plain>Bluestone, and C.M. </plain></SENT>
<SENT sid="308" pm="."><plain>Pearson. 1973. </plain></SENT>
<SENT sid="309" pm="."><plain>High association of an HL-A antigen, W27, with ankylosing spondylitis. N. </plain></SENT>
<SENT sid="310" pm="."><plain>Engl. </plain></SENT>
<SENT sid="311" pm="."><plain>J. </plain></SENT>
<SENT sid="312" pm="."><plain>Med. 288:704–706. <?supplied-pmid 4688372?>4688372 </plain></SENT>
</text></ref><ref id="bib11"><text><SENT sid="313" pm="."><plain>11Khan, M.A. 2002. </plain></SENT>
<SENT sid="314" pm="."><plain>Update on spondyloarthropathies. Ann. </plain></SENT>
<SENT sid="315" pm="."><plain>Intern. </plain></SENT>
<SENT sid="316" pm="."><plain>Med. 136:896–907. <?supplied-pmid 12069564?>12069564 </plain></SENT>
</text></ref><ref id="bib12"><text><SENT sid="317" pm="."><plain>12D'Amato, M., M.T. </plain></SENT>
<SENT sid="318" pm="."><plain>Fiorillo, C. </plain></SENT>
<SENT sid="319" pm="."><plain>Carcassi, A. </plain></SENT>
<SENT sid="320" pm="."><plain>Mathieu, A. </plain></SENT>
<SENT sid="321" pm="."><plain>Zuccarelli, P.P. </plain></SENT>
<SENT sid="322" pm="."><plain>Bitti, R. </plain></SENT>
<SENT sid="323" pm="."><plain>Tosi, and R. </plain></SENT>
<SENT sid="324" pm="."><plain>Sorrentino. 1995. </plain></SENT>
<SENT sid="325" pm="."><plain>Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur. </plain></SENT>
<SENT sid="326" pm="."><plain>J. </plain></SENT>
<SENT sid="327" pm="."><plain>Immunol. 25:3199–3201. <?supplied-pmid 7489765?>7489765 </plain></SENT>
</text></ref><ref id="bib13"><text><SENT sid="328" pm="."><plain>13Fiorillo, M.T., L. </plain></SENT>
<SENT sid="329" pm="."><plain>Meadows, M. </plain></SENT>
<SENT sid="330" pm="."><plain>D'Amato, J. </plain></SENT>
<SENT sid="331" pm="."><plain>Shabanowitz, D.F. </plain></SENT>
<SENT sid="332" pm="."><plain>Hunt, E. </plain></SENT>
<SENT sid="333" pm="."><plain>Appella, and R. </plain></SENT>
<SENT sid="334" pm="."><plain>Sorrentino. 1997. </plain></SENT>
<SENT sid="335" pm="."><plain>Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur. </plain></SENT>
<SENT sid="336" pm="."><plain>J. </plain></SENT>
<SENT sid="337" pm="."><plain>Immunol. 27:368–373. <?supplied-pmid 9045906?>9045906 </plain></SENT>
</text></ref><ref id="bib14"><text><SENT sid="338" pm="."><plain>14Ramos, M., A. </plain></SENT>
<SENT sid="339" pm="."><plain>Paradela, M. </plain></SENT>
<SENT sid="340" pm="."><plain>Vazquez, A. </plain></SENT>
<SENT sid="341" pm="."><plain>Marina, J. </plain></SENT>
<SENT sid="342" pm="."><plain>Vazquez, and J.A. </plain></SENT>
<SENT sid="343" pm="."><plain>Lopez de Castro. 2002. </plain></SENT>
<SENT sid="344" pm="."><plain>Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J. </plain></SENT>
<SENT sid="345" pm="."><plain>Biol. </plain></SENT>
<SENT sid="346" pm="."><plain>Chem. 277:28749–28756. <?supplied-pmid 12042320?>12042320 </plain></SENT>
</text></ref><ref id="bib15"><text><SENT sid="347" pm="."><plain>15Fiorillo, M.T., M. </plain></SENT>
<SENT sid="348" pm="."><plain>Maragno, R. </plain></SENT>
<SENT sid="349" pm="."><plain>Butler, M.L. </plain></SENT>
<SENT sid="350" pm="."><plain>Dupuis, and R. </plain></SENT>
<SENT sid="351" pm="."><plain>Sorrentino. 2000. </plain></SENT>
<SENT sid="352" pm="."><plain>CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J. </plain></SENT>
<SENT sid="353" pm="."><plain>Clin. </plain></SENT>
<SENT sid="354" pm="."><plain>Invest. 106:47–53. <?supplied-pmid 10880047?>10880047 </plain></SENT>
</text></ref><ref id="bib16"><text><SENT sid="355" pm="."><plain>16Brooks, J.M., R.J. </plain></SENT>
<SENT sid="356" pm="."><plain>Murray, W.A. </plain></SENT>
<SENT sid="357" pm="."><plain>Thomas, M.G. </plain></SENT>
<SENT sid="358" pm="."><plain>Kurilla, and A.B. </plain></SENT>
<SENT sid="359" pm="."><plain>Rickinson. 1993. </plain></SENT>
<SENT sid="360" pm="."><plain>Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. </plain></SENT>
<SENT sid="361" pm="."><plain>Exp. </plain></SENT>
<SENT sid="362" pm="."><plain>Med. 178:879–887. <?supplied-pmid 7688791?>7688791 </plain></SENT>
</text></ref><ref id="bib17"><text><SENT sid="363" pm="."><plain>17Del Porto, P., M. </plain></SENT>
<SENT sid="364" pm="."><plain>D'Amato, M.T. </plain></SENT>
<SENT sid="365" pm="."><plain>Fiorillo, L. </plain></SENT>
<SENT sid="366" pm="."><plain>Tuosto, E. </plain></SENT>
<SENT sid="367" pm="."><plain>Piccolella, and R. </plain></SENT>
<SENT sid="368" pm="."><plain>Sorrentino. 1994. </plain></SENT>
<SENT sid="369" pm="."><plain>Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta T cell clone. J. </plain></SENT>
<SENT sid="370" pm="."><plain>Immunol. 153:3093–3100. <?supplied-pmid 8089488?>8089488 </plain></SENT>
</text></ref><ref id="bib18"><text><SENT sid="371" pm="."><plain>18Menssen, R., P. </plain></SENT>
<SENT sid="372" pm="."><plain>Orth, A. </plain></SENT>
<SENT sid="373" pm="."><plain>Ziegler, and W. </plain></SENT>
<SENT sid="374" pm="."><plain>Saenger. 1999. </plain></SENT>
<SENT sid="375" pm="."><plain>Decamer-like conformation of a nona-peptide bound to HLA-B*3501 due to non-standard positioning of the C terminus. J. </plain></SENT>
<SENT sid="376" pm="."><plain>Mol. </plain></SENT>
<SENT sid="377" pm="."><plain>Biol. 285:645–653. <?supplied-pmid 9878435?>9878435 </plain></SENT>
</text></ref><ref id="bib19"><text><SENT sid="378" pm="."><plain>19Hülsmeyer, M., R.C. </plain></SENT>
<SENT sid="379" pm="."><plain>Hillig, A. </plain></SENT>
<SENT sid="380" pm="."><plain>Volz, M. </plain></SENT>
<SENT sid="381" pm="."><plain>Ruhl, W. </plain></SENT>
<SENT sid="382" pm="."><plain>Schroder, W. </plain></SENT>
<SENT sid="383" pm="."><plain>Saenger, A. </plain></SENT>
<SENT sid="384" pm="."><plain>Ziegler, and B. </plain></SENT>
<SENT sid="385" pm="."><plain>Uchanska-Ziegler. 2002. </plain></SENT>
<SENT sid="386" pm="."><plain>HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations. J. </plain></SENT>
<SENT sid="387" pm="."><plain>Biol. </plain></SENT>
<SENT sid="388" pm="."><plain>Chem. 277:47844–47853. <?supplied-pmid 12244049?>12244049 </plain></SENT>
</text></ref><ref id="bib20"><text><SENT sid="389" pm="."><plain>20Otwinowski, Z., and W. </plain></SENT>
<SENT sid="390" pm="."><plain>Minor. 1997 Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307–326. </plain></SENT>
</text></ref><ref id="bib21"><text><SENT sid="391" pm="."><plain>21Collaborative Computational Project Number 4. </plain></SENT>
<SENT sid="392" pm="."><plain>1994. </plain></SENT>
<SENT sid="393" pm="."><plain>The CCP4 Suite: Programs for Protein Crystallography. Acta. </plain></SENT>
<SENT sid="394" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="395" pm="."><plain>D. </plain></SENT>
<SENT sid="396" pm="."><plain>50:760–763. </plain></SENT>
</text></ref><ref id="bib22"><text><SENT sid="397" pm="."><plain>22Murshudov, G.N., A.A. </plain></SENT>
<SENT sid="398" pm="."><plain>Vagin, A. </plain></SENT>
<SENT sid="399" pm="."><plain>Lebedev, K.S. </plain></SENT>
<SENT sid="400" pm="."><plain>Wilson, and E.J. </plain></SENT>
<SENT sid="401" pm="."><plain>Dodson. 1999. </plain></SENT>
<SENT sid="402" pm="."><plain>Efficient anisotropic refinement of macromolecular structures using FFT. Acta. </plain></SENT>
<SENT sid="403" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="404" pm="."><plain>D. 55:247–255. <?supplied-pmid 10089417?>10089417 </plain></SENT>
</text></ref><ref id="bib23"><text><SENT sid="405" pm="."><plain>23Perrakis, A., R. </plain></SENT>
<SENT sid="406" pm="."><plain>Morris, and V.S. </plain></SENT>
<SENT sid="407" pm="."><plain>Lamzin. 1999. </plain></SENT>
<SENT sid="408" pm="."><plain>Automated protein model building combined with iterative structure refinement. Nat. </plain></SENT>
<SENT sid="409" pm="."><plain>Struct. </plain></SENT>
<SENT sid="410" pm="."><plain>Biol. 6:458–463. <?supplied-pmid 10331874?>10331874 </plain></SENT>
</text></ref><ref id="bib24"><text><SENT sid="411" pm="."><plain>24Jones, T.A., and M. </plain></SENT>
<SENT sid="412" pm="."><plain>Kjeldgaard. 1997 Electron-density map interpretation. Methods Enzymol. 277:173–208.18488310 </plain></SENT>
</text></ref><ref id="bib25"><text><SENT sid="413" pm="."><plain>25Winn, M.D., M.N. </plain></SENT>
<SENT sid="414" pm="."><plain>Isupov, and G.N. </plain></SENT>
<SENT sid="415" pm="."><plain>Murshudov. 2001. </plain></SENT>
<SENT sid="416" pm="."><plain>Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta. </plain></SENT>
<SENT sid="417" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="418" pm="."><plain>D. 57:122–133. <?supplied-pmid 11134934?>11134934 </plain></SENT>
</text></ref><ref id="bib26"><text><SENT sid="419" pm="."><plain>26Brünger, A.T., P.D. </plain></SENT>
<SENT sid="420" pm="."><plain>Adams, G.M. </plain></SENT>
<SENT sid="421" pm="."><plain>Clore, W.L. </plain></SENT>
<SENT sid="422" pm="."><plain>DeLano, P. </plain></SENT>
<SENT sid="423" pm="."><plain>Gros, R.W. </plain></SENT>
<SENT sid="424" pm="."><plain>Grosse-Kunstleve, J.S. </plain></SENT>
<SENT sid="425" pm="."><plain>Jiang, J. </plain></SENT>
<SENT sid="426" pm="."><plain>Kuszewski, M. </plain></SENT>
<SENT sid="427" pm="."><plain>Nilges, N.S. </plain></SENT>
<SENT sid="428" pm="."><plain>Pannu, et al. 1998. </plain></SENT>
<SENT sid="429" pm="."><plain>Crystallography &amp; NMR system: a new software suite for macromolecular structure determination. Acta. </plain></SENT>
<SENT sid="430" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="431" pm="."><plain>D. 54:905–921. <?supplied-pmid 9757107?>9757107 </plain></SENT>
</text></ref><ref id="bib27"><text><SENT sid="432" pm="."><plain>27Merritt, E.A. 1999. </plain></SENT>
<SENT sid="433" pm="."><plain>Expanding the model: anisotropic displacement parameters in protein structure refinement. Acta. </plain></SENT>
<SENT sid="434" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="435" pm="."><plain>D. 55:1109–1117. <?supplied-pmid 10329772?>10329772 </plain></SENT>
</text></ref><ref id="bib28"><text><SENT sid="436" pm="."><plain>28Laskowski, R.A., M.W. </plain></SENT>
<SENT sid="437" pm="."><plain>MacArthur, D.S. </plain></SENT>
<SENT sid="438" pm="."><plain>Moss, and J.M. </plain></SENT>
<SENT sid="439" pm="."><plain>Thornton. 1995 PROCHECK: a program to check the stereochemical quality of protein structures. J. </plain></SENT>
<SENT sid="440" pm="."><plain>Appl. </plain></SENT>
<SENT sid="441" pm="."><plain>Crystallogr. 26:283–291. </plain></SENT>
</text></ref><ref id="bib29"><text><SENT sid="442" pm="."><plain>29Hooft, R.W., G. </plain></SENT>
<SENT sid="443" pm="."><plain>Vriend, C. </plain></SENT>
<SENT sid="444" pm="."><plain>Sander, and E.E. </plain></SENT>
<SENT sid="445" pm="."><plain>Abola. 1996. </plain></SENT>
<SENT sid="446" pm="."><plain>Errors in protein structures. Nature. 381:272. <?supplied-pmid 8692262?>8692262 </plain></SENT>
</text></ref><ref id="bib30"><text><SENT sid="447" pm="."><plain>30McLachlan, A.D. 1982 Rapid comparison of protein structures. Acta. </plain></SENT>
<SENT sid="448" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="449" pm="."><plain>A. 38:871–873. </plain></SENT>
</text></ref><ref id="bib31"><text><SENT sid="450" pm="."><plain>31Nicholls, A., K.A. </plain></SENT>
<SENT sid="451" pm="."><plain>Sharp, and B. </plain></SENT>
<SENT sid="452" pm="."><plain>Honig. 1991. </plain></SENT>
<SENT sid="453" pm="."><plain>Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:281–296. <?supplied-pmid 1758883?>1758883 </plain></SENT>
</text></ref><ref id="bib32"><text><SENT sid="454" pm="."><plain>32Kraulis, P.J. 1991 MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. </plain></SENT>
<SENT sid="455" pm="."><plain>Appl. </plain></SENT>
<SENT sid="456" pm="."><plain>Crystallogr. 24:946–950. </plain></SENT>
</text></ref><ref id="bib33"><text><SENT sid="457" pm="."><plain>33Fenn, T.D., D. </plain></SENT>
<SENT sid="458" pm="."><plain>Ringe, and G.A. </plain></SENT>
<SENT sid="459" pm="."><plain>Petsko. 2003 POVScript+: a program for model and data visualization using persistence of vision ray-tracing. J. </plain></SENT>
<SENT sid="460" pm="."><plain>Appl. </plain></SENT>
<SENT sid="461" pm="."><plain>Crystallogr. 36:944–947. </plain></SENT>
</text></ref><ref id="bib34"><text><SENT sid="462" pm="."><plain>34Merritt, E.A., and D.J. </plain></SENT>
<SENT sid="463" pm="."><plain>Bacon. 1997 Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:505–524.18488322 </plain></SENT>
</text></ref><ref id="bib35"><text><SENT sid="464" pm="."><plain>35Sanner, M.F., A.J. </plain></SENT>
<SENT sid="465" pm="."><plain>Olson, and J.C. </plain></SENT>
<SENT sid="466" pm="."><plain>Spehner. 1996. </plain></SENT>
<SENT sid="467" pm="."><plain>Reduced surface: an efficient way to compute molecular surfaces. Biopolymers. 38:305–320. <?supplied-pmid 8906967?>8906967 </plain></SENT>
</text></ref><ref id="bib36"><text><SENT sid="468" pm="."><plain>36Madden, D.R., J.C. </plain></SENT>
<SENT sid="469" pm="."><plain>Gorga, J.L. </plain></SENT>
<SENT sid="470" pm="."><plain>Strominger, and D.C. </plain></SENT>
<SENT sid="471" pm="."><plain>Wiley. 1992. </plain></SENT>
<SENT sid="472" pm="."><plain>The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell. 70:1035–1048. <?supplied-pmid 1525820?>1525820 </plain></SENT>
</text></ref><ref id="bib37"><text><SENT sid="473" pm="."><plain>37Hillig, R.C., M. </plain></SENT>
<SENT sid="474" pm="."><plain>Huelsmeyer, W. </plain></SENT>
<SENT sid="475" pm="."><plain>Saenger, K. </plain></SENT>
<SENT sid="476" pm="."><plain>Welfle, R. </plain></SENT>
<SENT sid="477" pm="."><plain>Misselwitz, H. </plain></SENT>
<SENT sid="478" pm="."><plain>Welfle, C. </plain></SENT>
<SENT sid="479" pm="."><plain>Kozerski, A. </plain></SENT>
<SENT sid="480" pm="."><plain>Volz, B. </plain></SENT>
<SENT sid="481" pm="."><plain>Uchanska-Ziegler, and A. </plain></SENT>
<SENT sid="482" pm="."><plain>Ziegler. </plain></SENT>
<SENT sid="483" pm="."><plain>2003. </plain></SENT>
<SENT sid="484" pm="."><plain>Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J. </plain></SENT>
<SENT sid="485" pm="."><plain>Biol. </plain></SENT>
<SENT sid="486" pm="."><plain>Chem. 10.1074/jbc. </plain></SENT>
<SENT sid="487" pm="."><plain>M307457200. </plain></SENT>
</text></ref><ref id="bib38"><text><SENT sid="488" pm="."><plain>38Harding, M.M. 2001. </plain></SENT>
<SENT sid="489" pm="."><plain>Geometry of metal-ligand interactions in proteins. Acta. </plain></SENT>
<SENT sid="490" pm="."><plain>Crystallogr. </plain></SENT>
<SENT sid="491" pm="."><plain>D. </plain></SENT>
<SENT sid="492" pm="."><plain>Biol. </plain></SENT>
<SENT sid="493" pm="."><plain>Crystallogr. 57:401–411. <?supplied-pmid 11223517?>11223517 </plain></SENT>
</text></ref><ref id="bib39"><text><SENT sid="494" pm="."><plain>39Speir, J.A., J. </plain></SENT>
<SENT sid="495" pm="."><plain>Stevens, E. </plain></SENT>
<SENT sid="496" pm="."><plain>Joly, G.W. </plain></SENT>
<SENT sid="497" pm="."><plain>Butcher, and I.A. </plain></SENT>
<SENT sid="498" pm="."><plain>Wilson. 2001. </plain></SENT>
<SENT sid="499" pm="."><plain>Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity. 14:81–92. <?supplied-pmid 11163232?>11163232 </plain></SENT>
</text></ref><ref id="bib40"><text><SENT sid="500" pm="."><plain>40Uchanska-Ziegler, B., U. </plain></SENT>
<SENT sid="501" pm="."><plain>Alexiev, R.C. </plain></SENT>
<SENT sid="502" pm="."><plain>Hillig, M. </plain></SENT>
<SENT sid="503" pm="."><plain>Hülsmeyer, T. </plain></SENT>
<SENT sid="504" pm="."><plain>Pöhlmann, W. </plain></SENT>
<SENT sid="505" pm="."><plain>Saenger, A. </plain></SENT>
<SENT sid="506" pm="."><plain>Volz, and A. </plain></SENT>
<SENT sid="507" pm="."><plain>Ziegler. 2003 X-ray Crystallography and Dynamic Studies of HLA-B*2705 and B*2709 Molecules Complexed with the Same Peptide. IHWG Press, Seattle, WA. In press. </plain></SENT>
</text></ref><ref id="bib41"><text><SENT sid="508" pm="."><plain>41Von Boehmer, H., I. </plain></SENT>
<SENT sid="509" pm="."><plain>Aifantis, F. </plain></SENT>
<SENT sid="510" pm="."><plain>Gounari, O. </plain></SENT>
<SENT sid="511" pm="."><plain>Azogui, L. </plain></SENT>
<SENT sid="512" pm="."><plain>Haughn, I. </plain></SENT>
<SENT sid="513" pm="."><plain>Apostolou, E. </plain></SENT>
<SENT sid="514" pm="."><plain>Jaeckel, F. </plain></SENT>
<SENT sid="515" pm="."><plain>Grassi, and L. </plain></SENT>
<SENT sid="516" pm="."><plain>Klein. 2003. </plain></SENT>
<SENT sid="517" pm="."><plain>Thymic selection revisited: how essential is it? Immunol. </plain></SENT>
<SENT sid="518" pm="."><plain>Rev. 191:62–78. <?supplied-pmid 12614352?>12614352 </plain></SENT>
</text></ref><ref id="bib42"><text><SENT sid="519" pm="."><plain>42Wu, L.C., D.S. </plain></SENT>
<SENT sid="520" pm="."><plain>Tuot, D.S. </plain></SENT>
<SENT sid="521" pm="."><plain>Lyons, K.C. </plain></SENT>
<SENT sid="522" pm="."><plain>Garcia, and M.M. </plain></SENT>
<SENT sid="523" pm="."><plain>Davis. 2002. </plain></SENT>
<SENT sid="524" pm="."><plain>Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature. 418:552–556. <?supplied-pmid 12152083?>12152083 </plain></SENT>
</text></ref><ref id="bib43"><text><SENT sid="525" pm="."><plain>43Housset, D., and B. </plain></SENT>
<SENT sid="526" pm="."><plain>Malissen. 2003. </plain></SENT>
<SENT sid="527" pm="."><plain>What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? Trends Immunol. 24:429–437. <?supplied-pmid 12909456?>12909456 </plain></SENT>
</text></ref><ref id="bib44"><text><SENT sid="528" pm="."><plain>44Cook, J.R., E.M. </plain></SENT>
<SENT sid="529" pm="."><plain>Wormstall, T. </plain></SENT>
<SENT sid="530" pm="."><plain>Hornell, J. </plain></SENT>
<SENT sid="531" pm="."><plain>Russell, J.M. </plain></SENT>
<SENT sid="532" pm="."><plain>Connolly, and T.H. </plain></SENT>
<SENT sid="533" pm="."><plain>Hansen. 1997. </plain></SENT>
<SENT sid="534" pm="."><plain>Quantitation of the cell surface level of Ld resulting in positive versus negative selection of the 2C transgenic T cell receptor in vivo. Immunity. 7:233–241. <?supplied-pmid 9285408?>9285408 </plain></SENT>
</text></ref><ref id="bib45"><text><SENT sid="535" pm="."><plain>45Delaney, J.R., Y. </plain></SENT>
<SENT sid="536" pm="."><plain>Sykulev, H.N. </plain></SENT>
<SENT sid="537" pm="."><plain>Eisen, and S. </plain></SENT>
<SENT sid="538" pm="."><plain>Tonegawa. 1998. </plain></SENT>
<SENT sid="539" pm="."><plain>Differences in the level of expression of class I major histocompatibility complex proteins on thymic epithelial and dendritic cells influence the decision of immature thymocytes between positive and negative selection. Proc. </plain></SENT>
<SENT sid="540" pm="."><plain>Natl. </plain></SENT>
<SENT sid="541" pm="."><plain>Acad. </plain></SENT>
<SENT sid="542" pm="."><plain>Sci. </plain></SENT>
<SENT sid="543" pm="."><plain>USA. 95:5235–5240. <?supplied-pmid 9560259?>9560259 </plain></SENT>
</text></ref><ref id="bib46"><text><SENT sid="544" pm="."><plain>46Ong, K.W., A.D. </plain></SENT>
<SENT sid="545" pm="."><plain>Wilson, T.R. </plain></SENT>
<SENT sid="546" pm="."><plain>Hirst, and A.J. </plain></SENT>
<SENT sid="547" pm="."><plain>Morgan. 2003. </plain></SENT>
<SENT sid="548" pm="."><plain>The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines. J. </plain></SENT>
<SENT sid="549" pm="."><plain>Virol. 77:4298–4305. <?supplied-pmid 12634387?>12634387 </plain></SENT>
</text></ref><ref id="bib47"><text><SENT sid="550" pm="."><plain>47Kuon, W., H.G. </plain></SENT>
<SENT sid="551" pm="."><plain>Holzhutter, H. </plain></SENT>
<SENT sid="552" pm="."><plain>Appel, M. </plain></SENT>
<SENT sid="553" pm="."><plain>Grolms, S. </plain></SENT>
<SENT sid="554" pm="."><plain>Kollnberger, A. </plain></SENT>
<SENT sid="555" pm="."><plain>Traeder, P. </plain></SENT>
<SENT sid="556" pm="."><plain>Henklein, E. </plain></SENT>
<SENT sid="557" pm="."><plain>Weiss, A. </plain></SENT>
<SENT sid="558" pm="."><plain>Thiel, R. </plain></SENT>
<SENT sid="559" pm="."><plain>Lauster, et al. 2001. </plain></SENT>
<SENT sid="560" pm="."><plain>Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J. </plain></SENT>
<SENT sid="561" pm="."><plain>Immunol. 167:4738–4746. <?supplied-pmid 11591805?>11591805 </plain></SENT>
</text></ref><ref id="bib48"><text><SENT sid="562" pm="."><plain>48Mason, D. 1998. </plain></SENT>
<SENT sid="563" pm="."><plain>A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. </plain></SENT>
<SENT sid="564" pm="."><plain>Today. 19:395–404. <?supplied-pmid 9745202?>9745202 </plain></SENT>
</text></ref><ref id="bib49"><text><SENT sid="565" pm="."><plain>49Ueno, T., H. </plain></SENT>
<SENT sid="566" pm="."><plain>Tomiyama, and M. </plain></SENT>
<SENT sid="567" pm="."><plain>Takiguchi. 2002. </plain></SENT>
<SENT sid="568" pm="."><plain>Single T cell receptor-mediated recognition of an identical HIV-derived peptide presented by multiple HLA class I molecules. J. </plain></SENT>
<SENT sid="569" pm="."><plain>Immunol. 169:4961–4969. <?supplied-pmid 12391209?>12391209 </plain></SENT>
</text></ref><ref id="bib50"><text><SENT sid="570" pm="."><plain>50Holler, P.D., L.K. </plain></SENT>
<SENT sid="571" pm="."><plain>Chlewicki, and D.M. </plain></SENT>
<SENT sid="572" pm="."><plain>Kranz. 2003. </plain></SENT>
<SENT sid="573" pm="."><plain>TCRs with high affinity for foreign pMHC show self-reactivity. Nat. </plain></SENT>
<SENT sid="574" pm="."><plain>Immunol. 4:55–62. <?supplied-pmid 12469116?>12469116 </plain></SENT>
</text></ref><ref id="bib51"><text><SENT sid="575" pm="."><plain>51Panoutsakopoulou, V., M.E. </plain></SENT>
<SENT sid="576" pm="."><plain>Sanchirico, K.M. </plain></SENT>
<SENT sid="577" pm="."><plain>Huster, M. </plain></SENT>
<SENT sid="578" pm="."><plain>Jansson, F. </plain></SENT>
<SENT sid="579" pm="."><plain>Granucci, D.J. </plain></SENT>
<SENT sid="580" pm="."><plain>Shim, K.W. </plain></SENT>
<SENT sid="581" pm="."><plain>Wucherpfennig, and H. </plain></SENT>
<SENT sid="582" pm="."><plain>Cantor. 2001. </plain></SENT>
<SENT sid="583" pm="."><plain>Analysis of the relationship between viral infection and autoimmune disease. Immunity. 15:137–147. <?supplied-pmid 11485745?>11485745 </plain></SENT>
</text></ref><ref id="bib52"><text><SENT sid="584" pm="."><plain>52Lang, H.L., H. </plain></SENT>
<SENT sid="585" pm="."><plain>Jacobsen, S. </plain></SENT>
<SENT sid="586" pm="."><plain>Ikemizu, C. </plain></SENT>
<SENT sid="587" pm="."><plain>Andersson, K. </plain></SENT>
<SENT sid="588" pm="."><plain>Harlos, L. </plain></SENT>
<SENT sid="589" pm="."><plain>Madsen, P. </plain></SENT>
<SENT sid="590" pm="."><plain>Hjorth, L. </plain></SENT>
<SENT sid="591" pm="."><plain>Sondergaard, A. </plain></SENT>
<SENT sid="592" pm="."><plain>Svejgaard, K. </plain></SENT>
<SENT sid="593" pm="."><plain>Wucherpfennig, et al. 2002. </plain></SENT>
<SENT sid="594" pm="."><plain>A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. </plain></SENT>
<SENT sid="595" pm="."><plain>Immunol. 3:940–943. <?supplied-pmid 12244309?>12244309 </plain></SENT>
</text></ref><ref id="bib53"><text><SENT sid="596" pm="."><plain>53Fiorillo, M.T., G. </plain></SENT>
<SENT sid="597" pm="."><plain>Greco, M. </plain></SENT>
<SENT sid="598" pm="."><plain>Maragno, I. </plain></SENT>
<SENT sid="599" pm="."><plain>Potolicchio, A. </plain></SENT>
<SENT sid="600" pm="."><plain>Monizio, M.L. </plain></SENT>
<SENT sid="601" pm="."><plain>Dupuis, and R. </plain></SENT>
<SENT sid="602" pm="."><plain>Sorrentino. 1998. </plain></SENT>
<SENT sid="603" pm="."><plain>The naturally occurring polymorphism Asp116→His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non-associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition. Eur. </plain></SENT>
<SENT sid="604" pm="."><plain>J. </plain></SENT>
<SENT sid="605" pm="."><plain>Immunol. 28:2508–2516. <?supplied-pmid 9710228?>9710228 </plain></SENT>
</text></ref><ref id="bib54"><text><SENT sid="606" pm="."><plain>54Reid, S.W., S. </plain></SENT>
<SENT sid="607" pm="."><plain>McAdam, K.J. </plain></SENT>
<SENT sid="608" pm="."><plain>Smith, P. </plain></SENT>
<SENT sid="609" pm="."><plain>Klenerman, C.A. </plain></SENT>
<SENT sid="610" pm="."><plain>O'Callaghan, K. </plain></SENT>
<SENT sid="611" pm="."><plain>Harlos, B.K. </plain></SENT>
<SENT sid="612" pm="."><plain>Jakobsen, A.J. </plain></SENT>
<SENT sid="613" pm="."><plain>McMichael, J.I. </plain></SENT>
<SENT sid="614" pm="."><plain>Bell, D.I. </plain></SENT>
<SENT sid="615" pm="."><plain>Stuart, and E.Y. </plain></SENT>
<SENT sid="616" pm="."><plain>Jones. 1996. </plain></SENT>
<SENT sid="617" pm="."><plain>Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J. </plain></SENT>
<SENT sid="618" pm="."><plain>Exp. </plain></SENT>
<SENT sid="619" pm="."><plain>Med. 184:2279–2286. <?supplied-pmid 8976183?>8976183 </plain></SENT>
</text></ref><ref id="bib55"><text><SENT sid="620" pm="."><plain>55Apostolopoulos, V., M. </plain></SENT>
<SENT sid="621" pm="."><plain>Yu, A.L. </plain></SENT>
<SENT sid="622" pm="."><plain>Corper, W. </plain></SENT>
<SENT sid="623" pm="."><plain>Li, I.F. </plain></SENT>
<SENT sid="624" pm="."><plain>McKenzie, L. </plain></SENT>
<SENT sid="625" pm="."><plain>Teyton, and I.A. </plain></SENT>
<SENT sid="626" pm="."><plain>Wilson. 2002. </plain></SENT>
<SENT sid="627" pm="."><plain>Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J. </plain></SENT>
<SENT sid="628" pm="."><plain>Mol. </plain></SENT>
<SENT sid="629" pm="."><plain>Biol. 318:1307–1316. <?supplied-pmid 12083519?>12083519 </plain></SENT>
</text></ref><ref id="bib56"><text><SENT sid="630" pm="."><plain>56Turnquist, H.R., E.L. </plain></SENT>
<SENT sid="631" pm="."><plain>Schenk, M.M. </plain></SENT>
<SENT sid="632" pm="."><plain>McIlhaney, H.D. </plain></SENT>
<SENT sid="633" pm="."><plain>Hickman, W.H. </plain></SENT>
<SENT sid="634" pm="."><plain>Hildebrand, and J.C. </plain></SENT>
<SENT sid="635" pm="."><plain>Solheim. 2002. </plain></SENT>
<SENT sid="636" pm="."><plain>Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics. 53:830–834. <?supplied-pmid 11862383?>11862383 </plain></SENT>
</text></ref><ref id="bib57"><text><SENT sid="637" pm="."><plain>57Gao, X., G.W. </plain></SENT>
<SENT sid="638" pm="."><plain>Nelson, P. </plain></SENT>
<SENT sid="639" pm="."><plain>Karacki, M.P. </plain></SENT>
<SENT sid="640" pm="."><plain>Martin, J. </plain></SENT>
<SENT sid="641" pm="."><plain>Phair, R. </plain></SENT>
<SENT sid="642" pm="."><plain>Kaslow, J.J. </plain></SENT>
<SENT sid="643" pm="."><plain>Goedert, S. </plain></SENT>
<SENT sid="644" pm="."><plain>Buchbinder, K. </plain></SENT>
<SENT sid="645" pm="."><plain>Hoots, D. </plain></SENT>
<SENT sid="646" pm="."><plain>Vlahov, et al. 2001. </plain></SENT>
<SENT sid="647" pm="."><plain>Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. </plain></SENT>
<SENT sid="648" pm="."><plain>Engl. </plain></SENT>
<SENT sid="649" pm="."><plain>J. </plain></SENT>
<SENT sid="650" pm="."><plain>Med. 344:1668–1675. <?supplied-pmid 11386265?>11386265 </plain></SENT>
</text></ref><ref id="bib58"><text><SENT sid="651" pm="."><plain>58Robinson, J., M.J. </plain></SENT>
<SENT sid="652" pm="."><plain>Waller, P. </plain></SENT>
<SENT sid="653" pm="."><plain>Parham, N. de Groot, R. </plain></SENT>
<SENT sid="654" pm="."><plain>Bontrop, L.J. </plain></SENT>
<SENT sid="655" pm="."><plain>Kennedy, P. </plain></SENT>
<SENT sid="656" pm="."><plain>Stoehr, and S.G. </plain></SENT>
<SENT sid="657" pm="."><plain>Marsh. 2003. </plain></SENT>
<SENT sid="658" pm="."><plain>IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic. </plain></SENT>
<SENT sid="659" pm="."><plain>Acids Res. 31:311–314. <?supplied-pmid 12520010?>12520010 </plain></SENT>
</text></ref><ref id="bib59"><text><SENT sid="660" pm="."><plain>59Hillig, R.C., P.G. </plain></SENT>
<SENT sid="661" pm="."><plain>Coulie, V. </plain></SENT>
<SENT sid="662" pm="."><plain>Stroobant, W. </plain></SENT>
<SENT sid="663" pm="."><plain>Saenger, A. </plain></SENT>
<SENT sid="664" pm="."><plain>Ziegler, and M. </plain></SENT>
<SENT sid="665" pm="."><plain>Hulsmeyer. 2001. </plain></SENT>
<SENT sid="666" pm="."><plain>High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J. </plain></SENT>
<SENT sid="667" pm="."><plain>Mol. </plain></SENT>
<SENT sid="668" pm="."><plain>Biol. 310:1167–1176. <?supplied-pmid 11502003?>11502003 </plain></SENT>
</text></ref><ref id="bib60"><text><SENT sid="669" pm="."><plain>60MacDonald, W.A., A.W. </plain></SENT>
<SENT sid="670" pm="."><plain>Purcell, N.A. </plain></SENT>
<SENT sid="671" pm="."><plain>Mifsud, L.K. </plain></SENT>
<SENT sid="672" pm="."><plain>Ely, D.S. </plain></SENT>
<SENT sid="673" pm="."><plain>Williams, L. </plain></SENT>
<SENT sid="674" pm="."><plain>Chang, J.J. </plain></SENT>
<SENT sid="675" pm="."><plain>Gorman, C.S. </plain></SENT>
<SENT sid="676" pm="."><plain>Clements, L. </plain></SENT>
<SENT sid="677" pm="."><plain>Kjer-Nielsen, D.M. </plain></SENT>
<SENT sid="678" pm="."><plain>Koelle, et al. 2003. </plain></SENT>
<SENT sid="679" pm="."><plain>A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J. </plain></SENT>
<SENT sid="680" pm="."><plain>Exp. </plain></SENT>
<SENT sid="681" pm="."><plain>Med. 198:679–691. <?supplied-pmid 12939341?>12939341 </plain></SENT>
</text></ref><ref id="bib61"><text><SENT sid="682" pm="."><plain>61Reche, P.A., and E.L. </plain></SENT>
<SENT sid="683" pm="."><plain>Reinherz. 2003. </plain></SENT>
<SENT sid="684" pm="."><plain>Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms. J. </plain></SENT>
<SENT sid="685" pm="."><plain>Mol. </plain></SENT>
<SENT sid="686" pm="."><plain>Biol. 331:623–641. <?supplied-pmid 12899833?>12899833 </plain></SENT>
</text></ref><ref id="bib62"><text><SENT sid="687" pm="."><plain>62Chen, W., J. </plain></SENT>
<SENT sid="688" pm="."><plain>McCluskey, S. </plain></SENT>
<SENT sid="689" pm="."><plain>Rodda, and F.R. </plain></SENT>
<SENT sid="690" pm="."><plain>Carbone. 1993. </plain></SENT>
<SENT sid="691" pm="."><plain>Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition. J. </plain></SENT>
<SENT sid="692" pm="."><plain>Exp. </plain></SENT>
<SENT sid="693" pm="."><plain>Med. 177:869–873. <?supplied-pmid 8436915?>8436915 </plain></SENT>
</text></ref><ref id="bib63"><text><SENT sid="694" pm="."><plain>63Luz, J.G., M. </plain></SENT>
<SENT sid="695" pm="."><plain>Huang, K.C. </plain></SENT>
<SENT sid="696" pm="."><plain>Garcia, M.G. </plain></SENT>
<SENT sid="697" pm="."><plain>Rudolph, V. </plain></SENT>
<SENT sid="698" pm="."><plain>Apostolopoulos, L. </plain></SENT>
<SENT sid="699" pm="."><plain>Teyton, and I.A. </plain></SENT>
<SENT sid="700" pm="."><plain>Wilson. 2002. </plain></SENT>
<SENT sid="701" pm="."><plain>Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing V(β) interactions. J. </plain></SENT>
<SENT sid="702" pm="."><plain>Exp. </plain></SENT>
<SENT sid="703" pm="."><plain>Med. 195:1175–1186. <?supplied-pmid 11994422?>11994422 </plain></SENT>
</text></ref><ref id="bib64"><text><SENT sid="704" pm="."><plain>64Sesma, L., V. </plain></SENT>
<SENT sid="705" pm="."><plain>Montserrat, J.R. </plain></SENT>
<SENT sid="706" pm="."><plain>Lamas, A. </plain></SENT>
<SENT sid="707" pm="."><plain>Marina, J. </plain></SENT>
<SENT sid="708" pm="."><plain>Vazquez, and J.A. </plain></SENT>
<SENT sid="709" pm="."><plain>Lopez de Castro. 2002. </plain></SENT>
<SENT sid="710" pm="."><plain>The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions. J. </plain></SENT>
<SENT sid="711" pm="."><plain>Biol. </plain></SENT>
<SENT sid="712" pm="."><plain>Chem. 277:16744–16749. <?supplied-pmid 11875071?>11875071 </plain></SENT>
</text></ref><ref id="bib65"><text><SENT sid="713" pm="."><plain>65Okamoto, K., S. </plain></SENT>
<SENT sid="714" pm="."><plain>Makino, Y. </plain></SENT>
<SENT sid="715" pm="."><plain>Yoshikawa, A. </plain></SENT>
<SENT sid="716" pm="."><plain>Takaki, Y. </plain></SENT>
<SENT sid="717" pm="."><plain>Nagatsuka, M. </plain></SENT>
<SENT sid="718" pm="."><plain>Ota, G. </plain></SENT>
<SENT sid="719" pm="."><plain>Tamiya, A. </plain></SENT>
<SENT sid="720" pm="."><plain>Kimura, S. </plain></SENT>
<SENT sid="721" pm="."><plain>Bahram, and H. </plain></SENT>
<SENT sid="722" pm="."><plain>Inoko. 2003. </plain></SENT>
<SENT sid="723" pm="."><plain>Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am. </plain></SENT>
<SENT sid="724" pm="."><plain>J. </plain></SENT>
<SENT sid="725" pm="."><plain>Hum. </plain></SENT>
<SENT sid="726" pm="."><plain>Genet. 72:303–312. <?supplied-pmid 12509789?>12509789 </plain></SENT>
</text></ref><ref id="bib66"><text><SENT sid="727" pm="."><plain>66Hofmann, M.A., S. </plain></SENT>
<SENT sid="728" pm="."><plain>Drury, B.I. </plain></SENT>
<SENT sid="729" pm="."><plain>Hudson, M.R. </plain></SENT>
<SENT sid="730" pm="."><plain>Gleason, W. </plain></SENT>
<SENT sid="731" pm="."><plain>Qu, Y. </plain></SENT>
<SENT sid="732" pm="."><plain>Lu, E. </plain></SENT>
<SENT sid="733" pm="."><plain>Lalla, S. </plain></SENT>
<SENT sid="734" pm="."><plain>Chitnis, J. </plain></SENT>
<SENT sid="735" pm="."><plain>Monteiro, M.H. </plain></SENT>
<SENT sid="736" pm="."><plain>Stickland, et al. 2002. </plain></SENT>
<SENT sid="737" pm="."><plain>RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3:123–135. <?supplied-pmid 12070776?>12070776 </plain></SENT>
</text></ref><ref id="bib67"><text><SENT sid="738" pm="."><plain>67Fiorillo, M.T., A. </plain></SENT>
<SENT sid="739" pm="."><plain>Cauli, C. </plain></SENT>
<SENT sid="740" pm="."><plain>Carcassi, P.P. </plain></SENT>
<SENT sid="741" pm="."><plain>Bitti, A. </plain></SENT>
<SENT sid="742" pm="."><plain>Vacca, G. </plain></SENT>
<SENT sid="743" pm="."><plain>Passiu, F. </plain></SENT>
<SENT sid="744" pm="."><plain>Bettosini, A. </plain></SENT>
<SENT sid="745" pm="."><plain>Mathieu, and R. </plain></SENT>
<SENT sid="746" pm="."><plain>Sorrentino. 2003. </plain></SENT>
<SENT sid="747" pm="."><plain>Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum. 48:1385–1389. <?supplied-pmid 12746911?>12746911 </plain></SENT>
</text></ref><ref id="bib68"><text><SENT sid="748" pm="."><plain>68Uchanska-Ziegler, B., and A. </plain></SENT>
<SENT sid="749" pm="."><plain>Ziegler. 2003. </plain></SENT>
<SENT sid="750" pm="."><plain>Ankylosing spondylitis: a beta2m-deposition disease? Trends Immunol. 24:73–76. <?supplied-pmid 12547503?>12547503 </plain></SENT>
</text></ref><ref id="bib69"><text><SENT sid="751" pm="."><plain>69Ferrara, G.B., A. </plain></SENT>
<SENT sid="752" pm="."><plain>Bacigalupo, T. </plain></SENT>
<SENT sid="753" pm="."><plain>Lamparelli, E. </plain></SENT>
<SENT sid="754" pm="."><plain>Lanino, L. </plain></SENT>
<SENT sid="755" pm="."><plain>Delfino, A. </plain></SENT>
<SENT sid="756" pm="."><plain>Morabito, A.M. </plain></SENT>
<SENT sid="757" pm="."><plain>Parodi, C. </plain></SENT>
<SENT sid="758" pm="."><plain>Pera, S. </plain></SENT>
<SENT sid="759" pm="."><plain>Pozzi, M.P. </plain></SENT>
<SENT sid="760" pm="."><plain>Sormani, et al. 2001. </plain></SENT>
<SENT sid="761" pm="."><plain>Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood. 98:3150–3155. <?supplied-pmid 11698304?>11698304 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
